---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046501"
form_type: "8-K"
ticker: "BAX"
cik: "0000010456"
company_name: "BAXTER INTERNATIONAL INC"
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:39:25.596053+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Baxter Q3 2024: continuing ops sales +4% to $2.7B; adj. EPS $0.80 beats guidance

## Summary
- Total sales (incl. discontinued ops) $3.85B; continuing ops sales $2.70B +4% YoY.
- GAAP diluted EPS from continuing ops $0.12; adjusted continuing ops EPS $0.49.
- Total Baxter GAAP diluted EPS $0.27; adjusted total diluted EPS $0.80, exceeding prior guidance.
- North Cove facility restarted highest-throughput IV solutions line after Hurricane Helene.
- Pending sale of Kidney Care business is a key milestone; hurricane expected to impact near-term financials.

## SEC filing metadata
- accession: 0001628280-24-046501
- form_type: 8-K
- ticker: BAX
- cik: 0000010456
- company_name: BAXTER INTERNATIONAL INC
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10456/000162828024046501/0001628280-24-046501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10456/000162828024046501/bax-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046501
- JSON: https://secwatch.observer/filing/0001628280-24-046501.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046501.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.